Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: Past, present and future

British Journal of Urology

Volumn 80, Issue 4, 1997, Pages 521-532

  Kirby, R S ^a   Pool, J L ^a,b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 5 METHYLURAPIDIL; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FINASTERIDE; INDORAMIN; PHENOXYBENZAMINE; PRAZOSIN; RECEPTOR SUBTYPE; STEROID 5ALPHA REDUCTASE; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ASTHENIA; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; EDEMA; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; MALE SEXUAL DYSFUNCTION; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION; SLOW RELEASE FORMULATION; SMOOTH MUSCLE TONE; SOMNOLENCE; SYNCOPE; TRANSURETHRAL RESECTION; TREATMENT INDICATION; URINE FLOW RATE; URINE INCONTINENCE; VASODILATATION; VERTIGO;

EID: 0031403359     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00247.x     Document Type: Review

References (63)

1. Barry MJ, Cockett ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351-8
2. Bartsch G, Müller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122: 487-91
3. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193-201
4. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836-9
5. Chapple CR, Aubry ML, James S et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol 1989; 63: 487-96
6. James S, Chapple CR, Phillips MI et al. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol 1989; 142: 438-44
7. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Quick Reference Guide for Clinicians. AHCPR Publication No. 94-0583. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. February 1994.
8. Chapple CR, Noble JG, Milroy EJG. Comparative study of selective α1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. Br J Urol 1993; 72: 822-5
9. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC and writing committee. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-7
10. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. New Engl J Med 1995; 332: 75-9
11. Ruffolo RR Jr. Nichols AJ, Stadel JM, Hieble JP. Structure and function of α-adrenoceptors. Pharmacol Rev 1991; 43: 475-505
12. Bylund DB, Eikenberg DC, Hieble JP et al. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev 1994; 46: 121-36
13. Ford APDW, Williams TJ, Blue DR, Clarke DE. α1-Adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol Sci 1994; 15: 167-70
14. Yamada S, Tanaka C, Kimura R, Kawabe K. Alpha1-adrenoceptors in human prostate: characterization and binding characteristics of alphal antagonists. Life Sci 1994; 54: 1845-54
15. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993; 45: 410-28
16. Kenny BA, Read AM, Naylor AM, Greengrass PM, Carter AJ, Wyllie MG. Effect of alphal adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urol 1994; 44: 52-6
17. Forray C, Bard JA, Wetzel JM et al. The α1-Adrenergic receptor that mediates smooth muscle contraction in the human prostate has the pharmacological properties of the cloned human α1c subtype. Mol Pharmacol 1994; 45: 703-9
18. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551-4
19. Abrams PH, Shah PJR, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982; 54: 527-30
20. Caine M, Perlberg S, Shapiro A. Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urol 1981; 17: 542-6
21. Reynolds JEF ed, Martindale. The Extra Pharmacopoeia, 30th Edn. London: The Pharmaceutical Press, 1993: 384
22. Thien TH, Delaere KPJ, DeBruyne FMJ, Koene RAP. Urinary incontinence caused by prazosin. Br Med J 1978; 1: 622-3
23. Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannigan M, Milroy EJG. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 1987; 60: 136-42
24. Hedlund H, Andersson K-E, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275-8
25. Chapple CR, Stott M, Abrams PH, Christmas TJ, Milroy EJG. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 1992; 70: 285-94
26. Jønler M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia: current pharmacological treatment. Drugs 1994; 47: 66-81
27. Fulton B, Wagstaff AJ, Sorkin EG. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320
28. Young RA, Brogden RN. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild to moderate hypertension. Drugs 1988; 35: 525-41
29. α1A-adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. Drugs of Today 1996; 32 (Suppl. C): 1-12
30. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993; 3: 258-77
31. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 164: 923-34
32. Buzelin JM, Hebert M, Blondin P and the PRAZALF Group. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72: 922-7
33. Lukacs B, McCarthy C, Grange JC. QOL BPH Study Group in General Practice. Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. Eur Urol 1993; 24 (Suppl. 1): 34-40
34. Jardin A, Bensadoun H, Delauche-Cavalier MC, Attali P. Alfuzosin in the treatment of benign prostate hypertrophy. Lancet 1991; 337: 1457-61
35. Abrams P, Schulman CC, Vaage S, and the European Tamsulosin Study Group. Tamsulosin, a selective α1C-adrenoceptor antagonist, a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995; 76: 325-36
36. α1A-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-67
37. α1A-adrenoceptor antagonist: an interim analysis of a multinational, multicentre open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 145-54
38. Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
39. Holme JB, Christensen MM, Rasmussen PC et al. 29-weeks doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 1994; 28: 77-82
40. Chapple CR, Carter P, Christmas TJ et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6
41. Janknegt RA, Chapple CR for the Doxazosin Study Groups. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Urol 1993; 24: 319-26
42. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K. Dias N for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
43. Gillenwater JY, Conn RL, Chrysant SG et al. for Multicenter Study Group. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5
44. Lepor H, Kaplan SA, Klimberg I et al. for the Multicenter Study Group. Doxazosin in benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1996 (in press).
45. Lepor H for the Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-13
46. Grimm RH, Grandits GA, Svendsen K for the TOMHS Research Group. Incidence and disappearance of erectile problems in men treated for stage I hypertension: the Treatment of Mild Hypertension Study (TOMHS). Eur Urol 1996; 30 (Suppl. 2): 26, #38
47. Neaton JD, Grimm RH, Prineas RJ et al. Treatment of mild hypertension study: final results. JAMA 1993; 270: 713-24
48. Kaplan SA, Meade D, Alisera P, Quinones S, Sold KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46: 512-7
49. Lowe F, Turtle J, Marks S, Steidle C, Jacobs T, Padley RJ for the HYCAT Investigator Group. Blood pressure effects of men with prostatism concurrently treated with antihypertensives and terazosin. J Urol 1995; 153: 272A, #176
50. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 1991; 121: 251-60
51. Pool JL. Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. Br J Clin Prac 1994; 74: 8-12
52. Chapple CR. Role of alpha-adrenergic blocking drugs in the treatment of bladder outflow obstruction. European Urology Update Series, 2: No. 21, European Board of Urology, London, 1993
53. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203-9
54. Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human smooth muscle. Prostate 1993; 22: 301-7
55. Shapiro E, Hartano V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297-307
56. Mobley DF. Doxazosin in patients with benign prostatic hyperplasia: effects as a function of baseline disease severity. J Urol 1996; 155: 571A, #1043
57. Roehrborn CG. The safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind placebo-controlled studies. Urology 1996 (in press)
58. Roehrborn CG, Oesterling JE, Auerbach S et al. for the HYCAT Investigator Group. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159-68
59. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, Chmiel JJ. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995; 45: 398-405
60. Lepor H for the VA Cooperative Studies BPH Study Group. A Department of Veterans Affairs (VA) Cooperative randomized placebo controlled clinical trial of the safety and efficacy of terazosin and finasteride monotherapy and terazosin/finasteride combination therapy in men with clinical BPH. J Urol 1996; 155: 587A, #1105
61. Lepor H, Welford WO, Barry MJ et al. The efficacy of terazosin, finasteride or both in benign prostate hyperplasia. N Engl J Med 1996; 335: 533-8
62. Walsh PC. Treatment of benign prostate hyperplasia. N Engl J Med 1996; 335: 586-7
63. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with flnasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405